

Ralf Schmidt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11493879/publications.pdf>

Version: 2024-02-01

29
papers

1,399
citations

586496

16
h-index

591227

27
g-index

29
all docs

29
docs citations

29
times ranked

1499
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 40, 116163.	1.4	11
2	Discovery of Covalent Bruton's Tyrosine Kinase Inhibitors with Decreased CYP2C8 Inhibitory Activity. <i>ChemMedChem</i> , 2021, 16, 3653-3662.	1.6	2
3	Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7643-7655.	2.9	99
4	Cyclic Dimers Of C-terminal $\hat{\text{I}}^{32}$ -MSH Analogs As Selective Antagonists Of The Human Sensory Nerve-Specific Receptor (SNSR-4). <i>Advances in Experimental Medicine and Biology</i> , 2009, 611, 111-112.	0.8	7
5	The galanin-R2 agonist AR-M1896 reduces glutamate toxicity in primary neural hippocampal cells. <i>Journal of Neurochemistry</i> , 2005, 95, 821-833.	2.1	48
6	Exploring Deltorphan II Binding to the Third Extracellular Loop of the $\hat{\text{I}}^{\text{r}}$ -Opioid Receptor. <i>Journal of Biological Chemistry</i> , 2004, 279, 21069-21077.	1.6	20
7	Sensory neuron-specific receptor activation elicits central and peripheral nociceptive effects in rats. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 7175-7180.	3.3	96
8	The Second Galanin Receptor GalR2 Plays a Key Role in Neurite Outgrowth from Adult Sensory Neurons. <i>Journal of Neuroscience</i> , 2003, 23, 416-421.	1.7	136
9	Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. <i>Nature Neuroscience</i> , 2002, 5, 201-209.	7.1	355
10	Effects of galanin receptor agonists on locus coeruleus neurons. <i>Brain Research</i> , 2001, 919, 169-174.	1.1	76
11	Novel Ligands Lacking a Positive Charge for the $\hat{\text{I}}^{\text{r}}$ - and $\hat{\text{I}}^{3/4}$ -Opioid Receptors. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 551-559.	2.9	51
12	N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: A Novel, Exceptionally Selective, Potent $\hat{\text{I}}^{\text{r}}$ Opioid Receptor Agonist with Oral Bioavailability and Its Analogues. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 3895-3905.	2.9	81
13	New Diarylmethylpiperazines as Potent and Selective Nonpeptidic $\hat{\text{I}}^{\text{r}}$ Opioid Receptor Agonists with Increased In Vitro Metabolic Stability. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 3878-3894.	2.9	118
14	Characterization of [^{125}I]AR-M100613, a high-affinity radioligand for $\hat{\text{I}}^{\text{r}}$ opioid receptors. <i>Peptides</i> , 1999, 20, 1327-1335.	1.2	9
15	Conformationally constrained opioid peptide analogs with novel activity profiles. <i>International Journal of Peptide Research and Therapeutics</i> , 1998, 5, 209-214.	0.1	0
16	Conformationally constrained opioid peptide analogs with novel activity profiles. <i>International Journal of Peptide Research and Therapeutics</i> , 1998, 5, 209-214.	0.1	10
17	Structural Modifications of the N-terminal Tetrapeptide Segment of [D-Ala 2]Deltorphan I: Effects on Opioid Receptor Affinities and Activities In Vitro and on Antinociceptive Potency. <i>Peptides</i> , 1997, 18, 1615-1621.	1.2	20
18	Proton NMR Conformational Analysis of Cyclic $\hat{\text{I}}^2$ -Casomorphin Analogues of the Type Tyr-cyclo[-N $\hat{\text{I}}^{\text{r}}$ -D-Orn-Xaa-Yaa-Gly-]. <i>Archiv Der Pharmazie</i> , 1996, 329, 133-142.	2.1	5

#	ARTICLE	IF	CITATIONS
19	Isolation and identification of peptide conformers by reversed-phase high-performance liquid chromatography and NMR at low temperature. <i>Journal of Chromatography A</i> , 1996, 729, 155-171.	1.8	46
20	Effect of aromatic amino acid substitutions in the 3 rd position of cyclic $\hat{\mu}$ -casomorphin analogues on $\hat{\mu}$ -opioid agonist/ δ -opioid antagonist properties*. <i>International Journal of Peptide and Protein Research</i> , 1996, 48, 411-419.	0.1	10
21	Distinct conformational preferences of three cyclic $\hat{\mu}$ -casomorphin $\hat{\mu}$ analogs determined using NMR spectroscopy and theoretical analysis. <i>International Journal of Peptide and Protein Research</i> , 1996, 48, 102-111.	0.1	13
22	The $\hat{\mu}$ Opioid Receptor Binding Pharmacophore Conformation of Ornithine Containing Cyclic $\hat{\mu}$ -Casomorphin Analogues and Related Peptides. <i>QSAR and Combinatorial Science</i> , 1995, 14, 417-426.	1.4	6
23	Structure-activity relationships of dermorphin analogues containing <i>N</i> -substituted amino acids in the 2 nd position of the peptide sequence. <i>International Journal of Peptide and Protein Research</i> , 1995, 46, 47-55.	0.1	38
24	Phe1-substituted $\hat{\mu}$ -casomorphin-5 analogues with analgesic activity. <i>Peptides</i> , 1994, 15, 457-460.	1.2	4
25	Cyclic $\hat{\mu}$ -Casomorphin Analogs with Mixed $\hat{\mu}$. Agonist/ δ . Antagonist Properties: Synthesis, Pharmacological Characterization, and Conformational Aspects. <i>Journal of Medicinal Chemistry</i> , 1994, 37, 1136-1144.	2.9	56
26	Hydrophobicity measurements of linear and related cyclic $\hat{\mu}$ -casomorphin peptides by RPHPLC. , 1993, , 467-468.		0
27	Linear and cyclic $\hat{\mu}$ -casomorphin analogues with high analgesic activity. <i>Peptides</i> , 1992, 13, 483-485.	1.2	11
28	Structure-activity relationships of cyclic $\hat{\mu}$ -casomorphin-5 analogues. <i>Peptides</i> , 1991, 12, 1175-1180.	1.2	20
29	Cyclization studies with tetra $\hat{\mu}$ and pentapeptide sequences corresponding to $\hat{\mu}$ -casomorphins. <i>International Journal of Peptide and Protein Research</i> , 1991, 37, 502-507.	0.1	51